232 related articles for article (PubMed ID: 38534956)
1. Paraneoplastic Syndromes in Neuroendocrine Prostate Cancer: A Systematic Review.
Abufaraj M; Ramadan R; Alkhatib A
Curr Oncol; 2024 Mar; 31(3):1618-1632. PubMed ID: 38534956
[TBL] [Abstract][Full Text] [Related]
2. Cushing Syndrome as a Manifestation of Neuroendocrine Prostate Cancer: A Rare Presentation Within a Rare Tumor.
Fernandes R; Dos Santos J; Reis F; Monteiro S
Cureus; 2021 Sep; 13(9):e18160. PubMed ID: 34703694
[TBL] [Abstract][Full Text] [Related]
3. Molecular mechanisms underlying the development of neuroendocrine prostate cancer.
Liu S; Alabi BR; Yin Q; Stoyanova T
Semin Cancer Biol; 2022 Nov; 86(Pt 3):57-68. PubMed ID: 35597438
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathological and immunological profiles of prostate adenocarcinoma and neuroendocrine prostate cancer.
Huang G; Zhang H; Shi H; Zhang W; Wang T; Wang Z; Chen Q; Lian B; Li J; Yang G
World J Surg Oncol; 2022 Dec; 20(1):407. PubMed ID: 36572885
[TBL] [Abstract][Full Text] [Related]
5. Prostate cancer, Hu antibodies and paraneoplastic neurological syndromes.
Storstein A; Raspotnig M; Vitaliani R; Giometto B; Graus F; Grisold W; Honnorat J; Vedeler CA
J Neurol; 2016 May; 263(5):1001-1007. PubMed ID: 27007485
[TBL] [Abstract][Full Text] [Related]
6. Preclinical Models of Neuroendocrine Prostate Cancer.
Cacciatore A; Albino D; Catapano CV; Carbone GM
Curr Protoc; 2023 May; 3(5):e742. PubMed ID: 37166213
[TBL] [Abstract][Full Text] [Related]
7. Review of Checkpoint Inhibitor Immunotherapy in Neuroendocrine Tumor of Prostate and Our Experience in 2 Cases.
Pokhrel A; Nair K; Jaswani V; Salyana M; Mooppan U; Wang JC
J Investig Med High Impact Case Rep; 2022; 10():23247096221093886. PubMed ID: 35473437
[TBL] [Abstract][Full Text] [Related]
8. Small Cell/Neuroendocrine Prostate Cancer: A Rare Treatment-Resistant Variant Presenting as Acute Onset Severe Back Pain.
Khine ST; Ajmal S; Azher Q; Singh A
Cureus; 2024 Jan; 16(1):e52379. PubMed ID: 38361678
[TBL] [Abstract][Full Text] [Related]
9. Diagnosis and management of neuroendocrine prostate cancer.
de Kouchkovsky I; Chan E; Schloss C; Poehlein C; Aggarwal R
Prostate; 2024 Apr; 84(5):426-440. PubMed ID: 38173302
[TBL] [Abstract][Full Text] [Related]
10. Genetic and epigenetic features of neuroendocrine prostate cancer and their emerging applications.
Zhang X; Barnett E; Smith J; Wilkinson E; Subramaniam RM; Zarrabi A; Rodger EJ; Chatterjee A
Int Rev Cell Mol Biol; 2024; 383():41-66. PubMed ID: 38359970
[TBL] [Abstract][Full Text] [Related]
11. Paraneoplastic syndromes: A focus on pathophysiology and supportive care.
Chung C; Allen E; Umoru G
Am J Health Syst Pharm; 2022 Nov; 79(22):1988-2000. PubMed ID: 35916756
[TBL] [Abstract][Full Text] [Related]
12. The long noncoding RNA H19 regulates tumor plasticity in neuroendocrine prostate cancer.
Singh N; Ramnarine VR; Song JH; Pandey R; Padi SKR; Nouri M; Olive V; Kobelev M; Okumura K; McCarthy D; Hanna MM; Mukherjee P; Sun B; Lee BR; Parker JB; Chakravarti D; Warfel NA; Zhou M; Bearss JJ; Gibb EA; Alshalalfa M; Karnes RJ; Small EJ; Aggarwal R; Feng F; Wang Y; Buttyan R; Zoubeidi A; Rubin M; Gleave M; Slack FJ; Davicioni E; Beltran H; Collins C; Kraft AS
Nat Commun; 2021 Dec; 12(1):7349. PubMed ID: 34934057
[TBL] [Abstract][Full Text] [Related]
13. Paraneoplastic syndromes in patients with nasopharyngeal cancer.
Toro C; Rinaldo A; Silver CE; Politi M; Ferlito A
Auris Nasus Larynx; 2009 Oct; 36(5):513-20. PubMed ID: 19111998
[TBL] [Abstract][Full Text] [Related]
14. Addressing the need for more therapeutic options in neuroendocrine prostate cancer.
Kemble J; Kwon ED; Karnes RJ
Expert Rev Anticancer Ther; 2023 Feb; 23(2):177-185. PubMed ID: 36698089
[TBL] [Abstract][Full Text] [Related]
15. Treatment-related neuroendocrine prostate cancer resulting in Cushing's syndrome.
Ramalingam S; Eisenberg A; Foo WC; Freedman J; Armstrong AJ; Moss LG; Harrison MR
Int J Urol; 2016 Dec; 23(12):1038-1041. PubMed ID: 27766686
[TBL] [Abstract][Full Text] [Related]
16. The β
Braadland PR; Ramberg H; Grytli HH; Urbanucci A; Nielsen HK; Guldvik IJ; Engedal A; Ketola K; Wang W; Svindland A; Mills IG; Bjartell A; Taskén KA
Mol Cancer Res; 2019 Nov; 17(11):2154-2168. PubMed ID: 31395667
[TBL] [Abstract][Full Text] [Related]
17. Clinical features of neuroendocrine prostate cancer.
Conteduca V; Oromendia C; Eng KW; Bareja R; Sigouros M; Molina A; Faltas BM; Sboner A; Mosquera JM; Elemento O; Nanus DM; Tagawa ST; Ballman KV; Beltran H
Eur J Cancer; 2019 Nov; 121():7-18. PubMed ID: 31525487
[TBL] [Abstract][Full Text] [Related]
18. Comparative study of neuroendocrine acquisition and biomarker expression between neuroendocrine and usual prostatic carcinoma.
Xiao GQ; Ho G; Suen C; Hurth KM
Prostate; 2021 Jun; 81(8):469-477. PubMed ID: 33848377
[TBL] [Abstract][Full Text] [Related]
19. [Clinical features of urological malignancies with paraneoplastic syndromes].
Yang Y; Mao QZ; Li HZ; Rong S; Yan WG; Ji ZG; Liu GH; Xu WF; Xiao H; Wang HJ
Zhonghua Yi Xue Za Zhi; 2010 Dec; 90(48):3411-4. PubMed ID: 21223815
[TBL] [Abstract][Full Text] [Related]
20. Association of intraductal carcinoma of the prostate detected by initial histological specimen and neuroendocrine prostate cancer: A report of three cases.
Ikeda J; Ohe C; Ohsugi H; Matsuda T; Tsuta K; Kinoshita H
Pathol Int; 2021 Sep; 71(9):621-626. PubMed ID: 34297443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
